Key Highlights
- Moderna (NASDAQ:MRNA) fell 4.30% pre-market to a listed USD 213.74 on 188,532 shares, with a market capitalization of USD 85.33 billion and an RSI of 65.6 labeled Strong up.
- Moderna fell 4.30% pre-market, with European quotes near EUR 190.49 on October 13 versus EUR 202.00 on October 12, and no new company release was found.
- Citi downgraded the stock to Sell with a USD 80 target on September 30, and the consensus target is about USD 122.67 with a Hold rating among 23 analysts, far below the USD 213.74 listed price.
- A price far above analyst targets and a binary data event on October 24 make the stock vulnerable to profit-taking.
What Is Moving the Stock
Moderna fell 4.30% pre-market, with European quotes near EUR 190.49 on October 13 versus EUR 202.00 on October 12, and no new company release was found. The next catalyst is the full intismeran data at ESMO's Presidential Symposium, with an investor event on October 24.
The Data Behind the Move
Citi downgraded the stock to Sell with a USD 80 target on September 30, and the consensus target is about USD 122.67 with a Hold rating among 23 analysts, far below the USD 213.74 listed price. The stock fell about 7% on October 6, the market value is USD 85.33 billion, and the RSI of 65.6 is labeled Strong up. If the listed price is the pre-market quote, simple arithmetic puts the prior close near USD 223.34; if it is the last close, the implied pre-market price is near USD 204.55, so check a live quote. Pre-market traded value is only about USD 40.30 million, a tiny slice of the company's size, so few dollars set the price. Volume of 188,532 shares is meaningful for a pre-market session, and the screener tag reads No catalyst found, which classifies the catalyst and does not set direction.
Risks and What to Watch
A price far above analyst targets and a binary data event on October 24 make the stock vulnerable to profit-taking. What to watch next: the October 24 ESMO data and valuation. This is information only and not investment advice. Futures were muted on Tuesday morning with JPMorgan, Wells Fargo, Goldman Sachs and Citigroup reporting before the bell, and JPMorgan's EPS of USD 5.57 missed a USD 5.90 forecast before the stock recovered. South Korea's Kospi fell 5.5% on memory valuation concerns and China competition, Nasdaq 100 futures were down about 0.5%, and S&P 500 third-quarter earnings are expected to grow 30.6%. Bank of America and Morgan Stanley report on Wednesday, September CPI data is due the same day, and the Fed meets on October 27 and 28. Oil traded above USD 100 a barrel on Iran and Strait of Hormuz supply risks, and the 10-year Treasury yield touched about 5.35% last week. Pre-market trading runs from 4:00 AM ET with thin volume, so prices react fastest to news and can shift again once the 9:30 AM ET open brings full liquidity.
Where Things Stand
Market conditions frame the day: futures were muted as big banks report, the Kospi fell 5.5% and chip and memory stocks were under pressure. Moderna (NASDAQ:MRNA) is moving with profit-taking before the October 24 data. A pre-market drop on this volume can reverse once regular trading opens, so the balance of evidence favors waiting for confirmation from filings and the open. Direction remains unknown, and the next catalyst is the October 24 ESMO data and valuation. Check the underlying filings first, verify the latest filings before acting, and treat the figures as a snapshot.






Please wait processing your request...